Connect Biopharma (CNTB) Projected to Post Earnings on Wednesday

Connect Biopharma (NASDAQ:CNTB) is expected to be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Connect Biopharma to post earnings of ($0.27) per share and revenue of $0.12 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Connect Biopharma (NASDAQ:CNTB) last posted its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The firm had revenue of $2.75 million for the quarter, compared to analyst estimates of $0.74 million. On average, analysts expect Connect Biopharma to post ($1.09) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

Connect Biopharma Stock Down 0.4%

CNTB opened at $0.77 on Wednesday. The stock has a fifty day moving average of $1.30 and a 200-day moving average of $2.18. The company has a market capitalization of $48.75 million, a P/E ratio of -0.65 and a beta of 0.06. Connect Biopharma has a fifty-two week low of $0.73 and a fifty-two week high of $3.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37.

Analyst Upgrades and Downgrades

Several research firms recently commented on CNTB. Leerink Partners began coverage on shares of Connect Biopharma in a research note on Monday, October 12th. They issued an “outperform” rating and a $4.00 price target on the stock. Canaccord Genuity Group dropped their price objective on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, September 16th. Weiss Ratings downgraded shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. Wall Street Zen lowered shares of Connect Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Connect Biopharma in a report on Wednesday, October 28th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.88.

About Connect Biopharma

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases driven by T-cell activity. The company’s research programs target conditions in immunology, including inflammatory bowel disease, atopic dermatitis and other immune-mediated disorders.

Its pipeline has included rademikibart, formerly known as CBP-201, an investigational monoclonal antibody designed to block the interleukin-4 receptor alpha pathway, and ropsacitinib, formerly known as CBP-307, an investigational oral TYK2 inhibitor.